Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2016-001042-25-Outside-EU/EEA
EUCTR2016-001042-25-Outside-EU/EEA
Active, not recruiting
Phase 1

A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation

F. Hoffmann-La Roche AG0 sites720 target enrollmentOctober 3, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRenal TransplantationMedDRA version: 19.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 100000004865Therapeutic area: Body processes [G] - Immune system processes [G12]
DrugsCellCept

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Renal Transplantation
Sponsor
F. Hoffmann-La Roche AG
Enrollment
720
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 3, 2016
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- male or female patients 13\-75 years of age
  • •\- single organ recipient (kidney only) from living (related or unrelated) or cadaveric heart\-beating donors
  • •\- patient receiving first or second kidney transplant
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 20
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 650
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 50

Exclusion Criteria

  • •\- immunosuppressive therapy (except corticosteroid treatment) within previous 28 days for a first transplant and 3 months for a second transplant
  • •\- history of malignancy in last 5 years (except successfully treated localized non\-melanoma skin cancer)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Impact of pharmaceutical care in schizophrenic patientsHealth Condition 1: F209- Schizophrenia, unspecified
CTRI/2022/10/046427Dr Deepak C G
Not yet recruiting
Phase 4
Warfarin pharmacogenetics
PACTR202103893112947Ilhaam Fredericks60
Not yet recruiting
Not Applicable
An intervention study for influenza prevention among school childreinfluenza
JPRN-UMIN000039022iigata University160
Completed
Not Applicable
A study to assess pharmacokinetic interactions by evaluating the effect of red ginseng in healthy Korean adultsSymptoms, signs and abnormal clinical and laboratory findings, NEC
KCT0002418Kyungpook National University Hospital15
Not yet recruiting
Phase 2
A Pharmacokinetic study Of Basti in Humans
CTRI/2022/09/045276Dr Kusuma H